Michel Van Houdt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michel Van Houdt has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Jessy Elst
Universiteit Antwerpen Faculteit geneeskunde en gezondheidswetenschappen
13 shared publications - Christel Mertens
Immunology–Allergology–Rheumatology, Faculty of Medicine and Health Sciences Antwerp University, Hospital, Infla‐Med Centre of Excellence, Antwerp University, University of Antwerp Antwerp Belgium
12 shared publications - Didier Gaston Ebo
Universiteit Antwerpen Faculteit geneeskunde en gezondheidswetenschappen
12 shared publications - Vito Sabato
Department of Immunology, Allergology, Rheumatology, the Infla‐Med Centre of Excellence, Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium
12 shared publications - Margo Maria Hagendorens
Immunology–Allergology–Rheumatology, Faculty of Medicine and Health Sciences Antwerp University, Hospital, Infla‐Med Centre of Excellence, Antwerp University, University of Antwerp Antwerp Belgium
9 shared publications - Michiel Beyens
Department of Immunology, Allergology, Rheumatology, the Infla‐Med Centre of Excellence, Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium
8 shared publications
Latest Publications
Non‐Releasers in the Basophil Activation Test: A Roadmap for the Correct Reporting and Interpretation
Flow cytometric analysis of activated basophils, known as the basophil activation test (BAT), is a tool available for the diagnosis of IgE‐mediated allergic reactions. Despite its reported clinical utility, around 10%–20% of tested subjects fall into the category of basophil non‐releasers, meaning that their basophils fail to degranulate upon IgE‐mediated stimulation in vitro. Several factors causing this non‐releaser status have been identified, but we currently lack a unified nomenclature to define such inconclusive BAT results and the practical steps to minimize such outcomes. In accordance with the STAndards for the Reporting of Diagnostic accuracy studies (STARD) statement, non‐releasers must be reported and considered in the calculation of clinical BAT performance metrics, as failure to do so significantly limits the broader implementation of BAT in routine practice. This review provides an overview of intrinsic and extrinsic factors responsible for the basophil non‐releaser phenotype in BAT. Furthermore, it proposes a standardized nomenclature for consistently reporting and integrating inconclusive BAT results in the diagnostic performance metrics and suggests diagnostic algorithms to facilitate their interpretation in clinical practice.
Non‐Releasers in the Basophil Activation Test: A Roadmap for the Correct Reporting and Interpretation
Flow cytometric analysis of activated basophils, known as the basophil activation test (BAT), is a tool available for the diagnosis of IgE‐mediated allergic reactions. Despite its reported clinical utility, around 10%–20% of tested subjects fall into the category of basophil non‐releasers, meaning that their basophils fail to degranulate upon IgE‐mediated stimulation in vitro. Several factors causing this non‐releaser status have been identified, but we currently lack a unified nomenclature to define such inconclusive BAT results and the practical steps to minimize such outcomes. In accordance with the STAndards for the Reporting of Diagnostic accuracy studies (STARD) statement, non‐releasers must be reported and considered in the calculation of clinical BAT performance metrics, as failure to do so significantly limits the broader implementation of BAT in routine practice. This review provides an overview of intrinsic and extrinsic factors responsible for the basophil non‐releaser phenotype in BAT. Furthermore, it proposes a standardized nomenclature for consistently reporting and integrating inconclusive BAT results in the diagnostic performance metrics and suggests diagnostic algorithms to facilitate their interpretation in clinical practice.
- 29 July 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 243-251
Towards an Optimal Decision Threshold for Specific I g E to r C an s 3 the Non‐Specific Lipid Transfer Protein of Cannabis sativa
Background: Cannabis allergy is increasingly reported, with Can s 3 as a major allergen. Investigations into sensitisation to Can s 3 utilise sophisticated techniques, including the cytometric bead assay and the basophil activation test. This study aims to utilise a fluorescence enzyme immunoassay to quantify sIgE to Can s 3, employing a recombinant Can s 3 protein. Methods: This study included 104 cannabis allergic patients, 20 healthy controls and 70 exposed atopic controls. Specific IgE by a fluorescence enzyme immunoassay or cytometric bead assay and the basophil activation test all used the same recombinant allergen. Two‐graph ROC curves were used to determine the clinically validated allergen‐specific cut‐off for maximal sensitivity and specificity and to facilitate direct comparison of the test performances. Results: Twenty‐two individuals were non‐responding in the basophil activation test and were excluded from all analyses involving basophil activation test results. The clinically validated cut‐off points are > 0.16 kU A /L, ≥ 0.14 kU A /L and > 5% for a fluorescence enzyme immunoassay, cytometric bead assay and basophil activation test, respectively. Utilising these thresholds, the fluorescence enzyme immunoassay exhibited a sensitivity of 72% and specificity of 74%, the cytometric bead assay demonstrated a sensitivity of 49% and specificity of 89%. In responders, the basophil activation test exhibited a sensitivity of 51% and specificity of 82%. Remarkably, low positive fluorescence enzyme immunoassay results, particularly below 0.35 kU A /L, are negative for both cytometric bead assay and basophil activation test. Conversely, utilising the conventional threshold of > 0.35 kU A /L, the sIgE a fluorescence enzyme immunoassay results exhibited greater congruence with those of the cytometric bead assay and basophil activation test. Conclusion: This study underscores the complexity of establishing an optimal decision threshold for the sIgE rCan s 3 fluorescence enzyme immunoassay and indicates that the clinically validated decision cut‐off may not always represent the most efficacious approach.
- 29 July 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 243-251
Towards an Optimal Decision Threshold for Specific I g E to r C an s 3 the Non‐Specific Lipid Transfer Protein of Cannabis sativa
Background: Cannabis allergy is increasingly reported, with Can s 3 as a major allergen. Investigations into sensitisation to Can s 3 utilise sophisticated techniques, including the cytometric bead assay and the basophil activation test. This study aims to utilise a fluorescence enzyme immunoassay to quantify sIgE to Can s 3, employing a recombinant Can s 3 protein. Methods: This study included 104 cannabis allergic patients, 20 healthy controls and 70 exposed atopic controls. Specific IgE by a fluorescence enzyme immunoassay or cytometric bead assay and the basophil activation test all used the same recombinant allergen. Two‐graph ROC curves were used to determine the clinically validated allergen‐specific cut‐off for maximal sensitivity and specificity and to facilitate direct comparison of the test performances. Results: Twenty‐two individuals were non‐responding in the basophil activation test and were excluded from all analyses involving basophil activation test results. The clinically validated cut‐off points are > 0.16 kU A /L, ≥ 0.14 kU A /L and > 5% for a fluorescence enzyme immunoassay, cytometric bead assay and basophil activation test, respectively. Utilising these thresholds, the fluorescence enzyme immunoassay exhibited a sensitivity of 72% and specificity of 74%, the cytometric bead assay demonstrated a sensitivity of 49% and specificity of 89%. In responders, the basophil activation test exhibited a sensitivity of 51% and specificity of 82%. Remarkably, low positive fluorescence enzyme immunoassay results, particularly below 0.35 kU A /L, are negative for both cytometric bead assay and basophil activation test. Conversely, utilising the conventional threshold of > 0.35 kU A /L, the sIgE a fluorescence enzyme immunoassay results exhibited greater congruence with those of the cytometric bead assay and basophil activation test. Conclusion: This study underscores the complexity of establishing an optimal decision threshold for the sIgE rCan s 3 fluorescence enzyme immunoassay and indicates that the clinically validated decision cut‐off may not always represent the most efficacious approach.
Flow Cytometry‐Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review
Immediate drug hypersensitivity reactions (IDHRs) pose significant diagnostic challenges, often requiring potentially hazardous drug challenge testing (DCT). Flow cytometry‐based cellular tests including the basophil activation test (BAT), the mast cell activation test (MAT) and the T cell activation test (TAT) offer promising alternatives to reduce DCT reliance. While these tests are still in development, they demonstrate potential to compete with skin tests by providing superior diagnostic performance and improved patient safety by reducing the need for DCT. Furthermore, it is encouraging that these flow cytometry‐based tests are also suitable for challenging populations, such as children. Despite requiring specialised infrastructure, these tests have the potential to be cost‐effective when performed in reference centres and may offer unique mechanistic insights into immediate drug hypersensitivity reactions. However, further research is needed to validate their reliability, address pharmaceutical‐specific testing considerations, and potentially integrate them into clinical guidelines.
Flow Cytometry‐Assisted Analyses of Individual Human Basophils, Mast Cells and T Cells in the Diagnosis of Immediate Drug Hypersensitivity: A Review
Immediate drug hypersensitivity reactions (IDHRs) pose significant diagnostic challenges, often requiring potentially hazardous drug challenge testing (DCT). Flow cytometry‐based cellular tests including the basophil activation test (BAT), the mast cell activation test (MAT) and the T cell activation test (TAT) offer promising alternatives to reduce DCT reliance. While these tests are still in development, they demonstrate potential to compete with skin tests by providing superior diagnostic performance and improved patient safety by reducing the need for DCT. Furthermore, it is encouraging that these flow cytometry‐based tests are also suitable for challenging populations, such as children. Despite requiring specialised infrastructure, these tests have the potential to be cost‐effective when performed in reference centres and may offer unique mechanistic insights into immediate drug hypersensitivity reactions. However, further research is needed to validate their reliability, address pharmaceutical‐specific testing considerations, and potentially integrate them into clinical guidelines.
- 6 March 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (6) , 499-501
Bone Marrow Mast Cells in Systemic Mastocytosis Exhibit Aberrations in Histamine, Size and Granularity
- 6 March 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (6) , 499-501
Bone Marrow Mast Cells in Systemic Mastocytosis Exhibit Aberrations in Histamine, Size and Granularity
- 23 August 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (4) , 915-917
Morphine-specific IgE testing in the diagnosis of neuromuscular blocking agent allergy: proper use and interpretation
- 23 August 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (4) , 915-917
Morphine-specific IgE testing in the diagnosis of neuromuscular blocking agent allergy: proper use and interpretation
- 3 July 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (10) , 760-762
IgE‐Mediated Mast Cell Responses to Rocuronium: A Matter of Protonation Status
- 3 July 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (10) , 760-762
IgE‐Mediated Mast Cell Responses to Rocuronium: A Matter of Protonation Status
- 14 April 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (6) , 679-682
Dual intracellular staining of CD154 (CD40L) and cytokines at single‐cell level: A novel aid to document immediate hypersensitivity to amoxicillin
- 14 April 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (6) , 679-682
Dual intracellular staining of CD154 (CD40L) and cytokines at single‐cell level: A novel aid to document immediate hypersensitivity to amoxicillin
- 1 January 2023
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 29 (3) , 178-184
Recent Knowledge and Insights on the Mechanisms of Immediate Hypersensitivity and Anaphylaxis: IgE/FcεRI- and Non-IgE/FcεRI-Dependent Anaphylaxis
Immediate hypersensitivity reactions can pose a clinical and diagnostic challenge, mainly because of the multifarious clinical presentation and distinct underlying – frequently uncertain – mechanisms. Anaphylaxis encompasses all rapidly developing and life-threatening signs and may cause death. Evidence has accumulated that immediate hypersensitivity and anaphylaxis do not necessarily involve an allergen-specific immune response with cross-linking of specific IgE (sIgE) antibodies bound to their high-affinity IgE receptor (FcεRI) on the surface of mast cells (MCs) and basophils. Immediate hypersensitive and anaphylaxis can also result from alternative specific and nonspecific MC and basophils activation and degranulation, such as complementderived anaphylatoxins and off-target occupancy of MC and/or basophil surface receptors such as the Masrelated G protein-coupled receptor X2 (MRGPRX2). Degranulation of MCs and basophils results in the release of inflammatory mediators, which can be, depending on the underlying trigger, in a different spatiotemporal manner. In addition, hypersensitivity and anaphylaxis can occur entirely independently of MC and basophil degranulation, as observed in hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) that divert normal arachidonic acid metabolism by inhibiting the cyclooxygenase (COX)-1 isoenzyme. Finally, one should remember that anaphylaxis might be part of the phenotype of particular - sometimes poorly recognizable - conditions such as clonal MC diseases (e.g. mastocytosis) and MC activation syndrome (MCAS). This review provides a status update on the molecular mechanisms involved in both sIgE/FcεRI- and non-sIgE/FcεRIdependent immediate hypersensitivity and anaphylaxis. In conclusion, there is increasing evidence for alternative pathophysiological hypersensitivity and anaphylaxis endotypes that are phenotypically and biologically indistinguishable, which are frequently difficult to diagnose, mainly because of uncertainties associated with diagnostic tests that might not enable to unveil the underlying mechanism.
- 1 January 2023
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 29 (3) , 178-184
Recent Knowledge and Insights on the Mechanisms of Immediate Hypersensitivity and Anaphylaxis: IgE/FcεRI- and Non-IgE/FcεRI-Dependent Anaphylaxis
Immediate hypersensitivity reactions can pose a clinical and diagnostic challenge, mainly because of the multifarious clinical presentation and distinct underlying – frequently uncertain – mechanisms. Anaphylaxis encompasses all rapidly developing and life-threatening signs and may cause death. Evidence has accumulated that immediate hypersensitivity and anaphylaxis do not necessarily involve an allergen-specific immune response with cross-linking of specific IgE (sIgE) antibodies bound to their high-affinity IgE receptor (FcεRI) on the surface of mast cells (MCs) and basophils. Immediate hypersensitive and anaphylaxis can also result from alternative specific and nonspecific MC and basophils activation and degranulation, such as complementderived anaphylatoxins and off-target occupancy of MC and/or basophil surface receptors such as the Masrelated G protein-coupled receptor X2 (MRGPRX2). Degranulation of MCs and basophils results in the release of inflammatory mediators, which can be, depending on the underlying trigger, in a different spatiotemporal manner. In addition, hypersensitivity and anaphylaxis can occur entirely independently of MC and basophil degranulation, as observed in hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) that divert normal arachidonic acid metabolism by inhibiting the cyclooxygenase (COX)-1 isoenzyme. Finally, one should remember that anaphylaxis might be part of the phenotype of particular - sometimes poorly recognizable - conditions such as clonal MC diseases (e.g. mastocytosis) and MC activation syndrome (MCAS). This review provides a status update on the molecular mechanisms involved in both sIgE/FcεRI- and non-sIgE/FcεRIdependent immediate hypersensitivity and anaphylaxis. In conclusion, there is increasing evidence for alternative pathophysiological hypersensitivity and anaphylaxis endotypes that are phenotypically and biologically indistinguishable, which are frequently difficult to diagnose, mainly because of uncertainties associated with diagnostic tests that might not enable to unveil the underlying mechanism.